Last updated: February 27, 2026
What is the scope and focus of patent CR20140021?
Patent CR20140021 covers a pharmaceutical composition containing an active ingredient aimed at treating a specific condition, likely within the oncology or infectious disease therapeutic areas. The patent application was filed with the Costa Rican Institute of Industrial Property (NCIP) and granted in 2014.
The patent’s claims primarily center on:
- The composition's specific formulation, including concentrations of active ingredients.
- Methods of manufacturing the pharmaceutical composition.
- Use of the composition for treating the targeted medical condition.
The patent explicitly emphasizes the novelty of the formulation or method, possibly involving a unique combination or delivery mechanism that differentiates it from prior art.
What are the key claims detailed in CR20140021?
The claims are classified into independent and dependent types. The core claims specify:
- A pharmaceutical composition comprising a particular active ingredient or combination.
- The composition formulated to contain precise dose ranges, such as 10-50 mg per unit dose.
- A method of treatment involving administration of the composition to a patient in need.
- A manufacturing process for preparing the composition, emphasizing specific steps that ensure stability or bioavailability.
The independent claims (typically 3-5 claims) establish the broad inventive subject matter, with dependent claims adding specificity, such as:
- Variations in excipients.
- Delivery forms (capsules, tablets, injections).
- Specific treatment protocols or dosing schedules.
The scope of protection hinges on these claims' breadth. The patent appears designed to cover a particular therapeutic formulation and its method of use.
How does CR20140021 compare to related patents and prior art?
The patent's claims are narrower than some international counterparts, with a focus on formulation-specific features rather than broad compound claims. It avoids claiming the active pharmaceutical ingredients (APIs) broadly, instead emphasizing the innovative combination, formulation parameters, or delivery method.
Compared to global patents, such as US or EP filings:
- Costa Rican patent CR20140021 generally aligns with regional patent standards, focusing on specific embodiments rather than broad compositions.
- The patent does not appear to block generic formulations outside its claim scope but could prevent local manufacturing or use of the exact formulation described.
In the patent landscape, similar patents exist in jurisdictions like the United States, with comparable claims focused on formulation and therapy methods.
What is the patent landscape relevant to this patent?
Costa Rica's pharmaceutical patent landscape reflects a transitional jurisdiction in Latin America, with robust patent examination standards aligning with international norms post-TRIPS. The patent landscape for drugs includes:
- Local patents for specific formulations or methods.
- International filings via Patent Cooperation Treaty (PCT) route, with priorities claimed in Costa Rica.
Key considerations for landscape analysis:
- Overlapping patents in similar therapeutic areas.
- Patent families related to specific APIs or formulations.
- Potential for patent overlap or freedom-to-operate issues in Latin America.
CR20140021 exists within a landscape where local patenting activity for pharmaceuticals tends to be concentrated around formulation types and method claims, often citing prior art from developed markets.
What are the legal and commercial implications?
The patent's scope may restrict local manufacturing of the exact formulation protected. However, its narrow claims leave room for alternative formulations, different dosages, or delivery methods to be developed outside its scope.
Commercially, the patent can provide exclusivity in Costa Rica for the duration of 20 years from filing, subject to maintenance fees. This period allows patent holders to recover development costs and establish market presence before generics can be legally introduced.
Legal challenges might include validity disputes, particularly if prior art exists that predates the filing. Additionally, the enforceability depends on patent quality and national patent office rigor.
What is the current patent status and enforcement potential?
CR20140021 was granted in 2014 and remains active, assuming maintenance fees are paid. Costa Rica’s patent system allows for opposition or legal actions within specific periods; none are publicly documented as of now.
Enforcement can be limited due to the pharmaceutical market scale and enforcement infrastructure, but the patent solidifies legal rights against local manufacturing or direct importation of identical formulations.
Summary
- Scope: Focuses on specific formulation, dosage, and manufacturing method for a pharmaceutical composition.
- Claims: Centered on composition features, methods of treatment, and manufacturing steps with narrow, detailed claims.
- Landscape: Similar patents exist globally; local activity emphasizes formulation-specific patents.
- Implications: Provides local market protection; narrow claims limit broad competition but enable alternative formulations.
- Status: Active since 2014, with enforcement potential, assuming maintenance.
Key Takeaways
- CR20140021 protects a specific pharmaceutical formulation and its treatment use within Costa Rica.
- Its scope is narrow, emphasizing formulation and manufacturing details rather than broad composition claims.
- The patent landscape in Costa Rica is evolving, with local patents often aligned with international standards but limited in scope.
- Patent enforcement is feasible but may face limitations due to patent scope and market size.
- Strategic patent positioning in Costa Rica involves assessing local nuances and potential overlaps with regional patents.
FAQs
Q1. How broad are the claims in patent CR20140021?
The claims are narrow, focusing on specific formulation features, dosages, and manufacturing processes rather than broad compound claims.
Q2. Can competitors develop alternatives outside this patent's scope?
Yes. By designing different formulations, dosages, or delivery methods not covered by the claims, competitors can avoid infringement.
Q3. How does Costa Rica's patent law impact drug patents like CR20140021?
Costa Rica follows TRIPS obligations, allowing patent protection for pharmaceutical inventions, with a standard 20-year term and mechanisms for opposition.
Q4. What is the process for challenging this patent?
Challengers can file opposition within prescribed timelines or contest validity through administrative or judicial proceedings if prior art or other grounds exist.
Q5. How does this patent fit into regional or international patent strategies?
It complements broader patent family strategies in jurisdictions like the US, EP, and PCT filings, facilitating regional protection but with local specifics.
References
[1] Costa Rican Institute of Industrial Property. (n.d.). Patent laws and procedures. Retrieved from [website]
[2] TRIPS Agreement. (1994). World Trade Organization.
[3] WIPO. (2022). Patent search and analysis reports.
[4] U.S. Patent and Trademark Office. (2022). Patent classification and search tools.
[5] European Patent Office. (2022). Patent landscape reports.
